semaglutide

Novo Nordisk seeks FDA nod for oral diabetes pill
Novo Nordisk seeks FDA nod for oral diabetes pill
Drug Delivery Business News
Novo Nordisk
FDA
semaglutide
diabetes
Flag link:
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Fierce Pharma
Novo Nordisk
diabetes
Teva Pharmaceutical
Victoza
semaglutide
Flag link:
Novo bets on swift FDA review for oral diabetes drug semaglutide
Novo bets on swift FDA review for oral diabetes drug semaglutide
Endpoints
Novo Nordisk
earnings
semaglutide
FDA
Flag link:
The 20 Hottest Pipeline Drugs to Watch in 2019
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Flag link:
3 Biotechs With Potential Blockbusters Near the Finish Line
3 Biotechs With Potential Blockbusters Near the Finish Line
Motley Fool
Vertex Pharmaceuticals
VX-659 + tezacaftor + ivacaftor
Celgene
JCAR017
Novo Nordisk
semaglutide
Flag link:
Novo Nordisk’s Semaglutide Hits Mark in Type 2 Diabetes Trial
Novo Nordisk’s Semaglutide Hits Mark in Type 2 Diabetes Trial
BioSpace
Novo Nordisk
clinical trials
semaglutide
type 2 diabetes
Flag link:
Novo Nordisk trumpets more Januvia-topping data for oral semaglutide
Novo Nordisk trumpets more Januvia-topping data for oral semaglutide
Fierce Pharma
Novo Nordisk
semaglutide
Merck
Januvia
HbA1C
Flag link:
Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia
Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia
Fierce Pharma
Novo Nordisk
diabetes
semaglutide
Victoza
Merck
Januvia
Flag link:
Novo Nordisk's oral diabetes drug beats Jardiance in study
Novo Nordisk's oral diabetes drug beats Jardiance in study
Yahoo/Reuters
diabetes
Novo Nordisk
semaglutide
Jardiance
Eli Lilly
Flag link:
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Fierce Pharma
Novo Nordisk
obesity
semaglutide
Flag link:
In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
Endpoints
Novo Nordisk
Eli Lilly
diabetes
clinical trials
semaglutide
Trulicity
Flag link:
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Fierce Pharma
Novo Nordisk
semaglutide
Eli Lilly
Ozempic
Trulicity
Flag link:
5 Biggest New Drugs of 2018
5 Biggest New Drugs of 2018
Motley Fool
Gilead Sciences
Bictegravir/F/TAF
Novo Nordisk
semaglutide
Ozempic
Incyte
epacadostat
AbbVie
Rova-T
Celgene
ozanimod
Flag link:
These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News
These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News
Investors Business Daily
Europe
AstraZeneca
Lynparza
ovarian cancer
Novo Nordisk
diabetes
semaglutide
Flag link:
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
Flag link:
Novo gains FDA OK for semaglutide
Novo gains FDA OK for semaglutide
BioPharma Dive
Novo Nordisk
semaglutide
FDA
Ozempic
type 2 diabetes
Flag link:
Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide
Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide
Endpoints
Novo Nordisk
obesity
semaglutide
Flag link:
With FDA panel backing, Novo Nordisk prepares for semaglutide's potential launch
With FDA panel backing, Novo Nordisk prepares for semaglutide's potential launch
Fierce Biotech
FDA
Novo Nordisk
semaglutide
diabetes
Flag link:
Novo's experimental diabetes drug likely to compete with Trulicity
Novo's experimental diabetes drug likely to compete with Trulicity
Medical Marketing and Media
Novo Nordisk
diabetes
Trulicity
semaglutide
Flag link:
FDA gives Novo Nordisk top grades for its diabetes drug semaglutide, but retinopathy remains key
FDA gives Novo Nordisk top grades for its diabetes drug semaglutide, but retinopathy remains key
Endpoints
FDA
Novo Nordisk
diabetes
semaglutide
diabetic retinopathy
Flag link:

Pages